Search in:

Advanced search

Pharmacogenomics and Personalized Medicine Volume 8, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

Jiska M Balk1 Department of Toxicology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands

Guido RMM Haenen1 Department of Toxicology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, Maastricht, the NetherlandsCorrespondence[email protected]

Özgür M Koc2 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands

Ron Peters3 DSM Resolve, Geleen, the Netherlands

Aalt Bast1 Department of Toxicology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands

Wim JF van der Vijgh1 Department of Toxicology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands

Ger H Koek4 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands

show all

Pages 137-144 | Published online: 12 Aug 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

MarcellinPHepatitis B and hepatitis C in 2009Liver Int200929Suppl 11819207959
PubMed Web of Science ®Google Scholar
AlexopoulouAKarayiannisPInterferon-based combination treatment for chronic hepatitis C in the era of direct acting antiviralsAnn Gastroenterol201528556525608803
PubMedGoogle Scholar
CholongitasEPapatheodoridisGVSofosbuvir: a novel oral agent for chronic hepatitis CAnn Gastroenterol20142733133725332066
PubMedGoogle Scholar
IzquierdoLHelleFFrancoisCCastelainSDuverlieGBrochotESimeprevir for the treatment of hepatitis C virus infectionPharmgenomics Pers Med2014724124925206310
PubMedGoogle Scholar
HoofnagleJHSeeffLBPeginterferon and ribavirin for chronic hepatitis CN Engl J Med20063552444245117151366
PubMed Web of Science ®Google Scholar
NumataMKagawaTKojimaSDifferential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis CHepat Res Treat2010201070274821188199
PubMedGoogle Scholar
McHutchisonJGMannsMPatelKAdherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis CGastroenterology20021231061106912360468
PubMed Web of Science ®Google Scholar
IngersollKSCohenJThe impact of medication regimen factors on adherence to chronic treatment: a review of literatureJ Behav Med20083121322418202907
PubMed Web of Science ®Google Scholar
LaliberteFNelsonWWLefebvrePScheinJRRondeau-LeclaireJDuhMSImpact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patientsAdv Ther20122967569022898791
PubMed Web of Science ®Google Scholar
MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet200135895896511583749
PubMed Web of Science ®Google Scholar
AlamIStainbrookTCecilBKistlerKDEnhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registryAliment Pharmacol Ther20103253554220500732
PubMed Web of Science ®Google Scholar
MarcellinPChoustermanMFontangesTAdherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational studyLiver Int20113151652421382162
PubMed Web of Science ®Google Scholar
KripalaniSYaoXHaynesRBInterventions to enhance medication adherence in chronic medical conditions: a systematic reviewArch Intern Med200716754055017389285
PubMed Web of Science ®Google Scholar
HayesCNChayamaKEmerging treatments for chronic hepatitis CJ Formos Med Assoc201511420421525300586
PubMed Web of Science ®Google Scholar
HungCHLeeCMLuSNAnemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment responseLiver Int2006261079108617032408
PubMed Web of Science ®Google Scholar
TapperoGBallareMFarinaMNegroFSevere anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis CJ Hepatol199829103310349875657
PubMed Web of Science ®Google Scholar
European Association for Study of LiverEASL clinical practice guidelines: management of hepatitis C virus infectionJ Hepatol20146039242024331294
PubMed Web of Science ®Google Scholar
EvonDMEssermanDABonnerJERaoTFriedMWGolinCEAdherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistenceJ Viral Hepat20132053654923808992
PubMed Web of Science ®Google Scholar
Munoz-de-RuedaPRuiz-ExtremeraACandelJMPlasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patientsJ Clin Gastroenterol20124632833322105181
PubMed Web of Science ®Google Scholar
GluePThe clinical pharmacology of ribavirinSemin Liver Dis199919Suppl 1172410349689
PubMed Web of Science ®Google Scholar
FurusyoNMurataMOgawaERibavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological responseJ Antimicrob Chemother2011661127113921393126
PubMed Web of Science ®Google Scholar
BruchfeldALindahlKSchvarczRStahleLDosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysisTher Drug Monit20022470170812451285
PubMed Web of Science ®Google Scholar
KamarNChatelutEManolisELafontTIzopetJRostaingLRibavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal functionAm J Kidney Dis20044314014614712437
PubMed Web of Science ®Google Scholar
De FranceschiLFattovichGTurriniFHemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damageHepatology200031997100410733558
PubMed Web of Science ®Google Scholar
KrishnanSMDixitNMRibavirin-induced anemia in hepatitis C virus patients undergoing combination therapyPLoS Comput Biol20117e100107221304937
PubMed Web of Science ®Google Scholar
MorelloJRodriguez-NovoaSJimenez-NacherISorianoVUsefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis CJ Antimicrob Chemother2008621174118018931138
PubMed Web of Science ®Google Scholar
Peck-RadosavljevicMWichlasMHomoncik-KramlMRapid suppression of hematopoiesis by standard or pegylated interferon-alphaGastroenterology200212314115112105843
PubMed Web of Science ®Google Scholar
WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of ribavirin in patients with hepatitis C virusBr J Clin Pharmacol20066271071417118126
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date